Jove
Visualize
Contact Us

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

196
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
196
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

402
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
402
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

500
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
500
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

149
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
149
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

305
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
305
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Development Of Alcohol-resistant Extended-release Formulations: Regulatory Considerations And Formulation Strategies.
  1. Home
  3. Development Of Alcohol-resistant Extended-release Formulations: Regulatory Considerations And Formulation Strategies.

Related Experiment Video

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.4K

Development of Alcohol-Resistant Extended-Release Formulations: Regulatory Considerations and Formulation Strategies.

Ming Ji1, Nitin K Swarnakar2, Shanmuka Harish Chalamuri3

  • 1BASF Corp., Tarrytown, NY, 10591, USA.

Pharmaceutical Research
|January 14, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

This study developed extended-release (ER) formulations using polyvinyl acetate (PVAc) and polyvinylpyrrolidone (PVP-90) to prevent alcohol-induced dose dumping (ADD). Optimized formulations showed reduced ADD risk and maintained ER profiles, even after storage.

Keywords:
ADD guidelinealcohol resistencealcohol-induced dose dumping (ADD)polyvinyl acetate (PVAc) dispersionpolyvinylpyrrolidone (PVP) 90reservoir-type extended-release formulationsustained release coating

More Related Videos

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.5K
Techniques for the Evolution of Robust Pentose-fermenting Yeast for Bioconversion of Lignocellulose to Ethanol
14:53

Techniques for the Evolution of Robust Pentose-fermenting Yeast for Bioconversion of Lignocellulose to Ethanol

Published on: October 24, 2016

11.8K

Related Experiment Videos

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.4K
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.5K
Techniques for the Evolution of Robust Pentose-fermenting Yeast for Bioconversion of Lignocellulose to Ethanol
14:53

Techniques for the Evolution of Robust Pentose-fermenting Yeast for Bioconversion of Lignocellulose to Ethanol

Published on: October 24, 2016

11.8K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems

Background:

  • Alcohol-induced dose dumping (ADD) is a critical concern for modified-release formulations.
  • Polyvinyl acetate (PVAc) and polyvinylpyrrolidone (PVP-90) are polymers with potential for developing robust drug delivery systems.

Purpose of the Study:

  • To develop reservoir-type extended-release (ER) formulations resistant to alcohol-induced dose dumping (ADD).
  • To investigate the use of polyvinyl acetate (PVAc) and polyvinylpyrrolidone (PVP-90) in mitigating ADD.

Main Methods:

  • ER formulations were created using water-soluble and water-insoluble core diluents and binders.
  • Various PVAc with PVP-90 (3:1 w/w) coating levels were applied.
  • In vitro risk mitigation studies assessed polymer and film properties (viscosity, swelling, elasticity, breaking force) under alcohol exposure.

Main Results:

  • Formulations with L-PVP in the core showed no burst release in alcohol but had compromised ADD resistance at lower coating levels.
  • Higher PVP-90 concentrations in the core slowed disintegration; >15% prevented disintegration in 0.1N HCl with 40% alcohol.
  • The optimized formulation (25% PVP-90 core, PVAc with PVP-90 coating) minimized ADD risk and maintained ER release after 3 months of accelerated storage.

Conclusions:

  • Core and coating compositions are crucial for achieving ADD resistance in ER formulations.
  • Even formulations meeting current FDA guidelines may exhibit dose dumping, suggesting a need to review regulatory standards.
  • Harmonizing regulatory requirements between agencies like EMA and US FDA is necessary for relevant in vitro ADD assessment methods.